Allergan blames loss of 1,000 jobs on competition

4 January 2018

Ireland-incorporated drugmaker Allergan (NYSE: AGN) has announced that it will cut more than 1,000 jobs in response to ‘the anticipated loss of exclusivity of several key revenue-generating products in 2018’.

Chief executive Brent Saunders warned in November that the loss of exclusivity of the dry-eye treatment Restasis (cyclosporine ophthalmic emulsion), Allergan’s second-biggest selling product, would necessitate cost-cutting, so the job losses were not unexpected.

Restasis brought in sales of around $1.5 billion for Allergan in 2016, but after a court ruling in October opened the way for competitors such as Mylan (Nasdaq: MYL) and Teva Pharmaceutical Industries (NYSE: TEVA) to launch generic versions.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK